Clinical trial · Observational
Towards Optimal Prescription of Chemotherapy in Prostate Cancer
TOward Personalizing Care for Older Men With mCRPC - Understanding and Predicting Treatment Toxicities (the TOPCOP Study)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will examine the impact of modern treatments for metastatic Castrate Resistant Prostate Cancer (mCRPC) on several relevant 'geriatric' domains such as daily function, objective physical function, and falls. Additionally, the investigators study whether frailty is associated with worse outcomes, and whether it is possible to predict the risk of severe chemotherapy toxicity in older men.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- Chemotherapy
- description
- Men starting first-line chemotherapy for mCRPC (typically Docetaxel and Prednisone)
- label
- Abiraterone
- description
- Men with mCRPC starting Abiraterone
- label
- Enzalutamide
- description
- Men with mCRPC starting Enzalutamide
Primary outcomes (5)
- measure
- Daily function assessed by questionnaires
- timeFrame
- Participants will be followed for the duration of treatment up to 2 years
- description
- Daily function
- measure
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. At least 65 years of age 2. Diagnosed with prostate cancer with evidence of clinical and/or radiographic evidence of progression despite adequate androgen deprivation therapy and achievement of castration (total testosterone level \<1.7 nmol/L measured within 6 months of enrollment) 3. Among men starting either abiraterone or enzalutamide, no prior chemotherapy/abiraterone/enzalutamide. Among men starting first-line chemotherapy, commencing docetaxel but can have had either prior abiraterone or enzalutamide Exclusion Criteria: 1. Unable to speak English fluently. 2. Severe neuropsychiatric abnormalities that prevent study participation. 3. Limited life expectancy (\<3 months) as estimated by the primary oncologist.
References
Publications (0)
Data not yet available